Careful neuro−cognitive and growth−plate monitoring is essential because paediatric TRK or RET inhibitor trials report mostly grade−1/2 neuropathy, transient liver enzyme rise, weight gain, physeal thickening and occasional hypertension—usually reversible with dose adjustment (5, 26). The gene discussed is RET; the disease is neuropathy.